A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease.

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 22, 2022

Primary Completion Date

July 18, 2024

Study Completion Date

July 18, 2024

Conditions
Parkinson Disease
Interventions
DRUG

RO7486967

For up to approximately 28 days

DRUG

Placebo

For up to approximately 28 days

Trial Locations (17)

10065

Weill Cornell Medical College, New York

19104

University Pennsylvania Hospital, Philadelphia

20007

Georgetown University, Washington D.C.

32804

Advent Health Orlando, Orlando

35294

University of Alabama at Birmingham, Birmingham

48334

Quest Research Institute, Farmington Hills

74136

The Movement Disorder Clinic of Oklahoma, Tulsa

80113

CenExel Rocky Mountain Clinical Research, LLC, Englewood

90048

Cedars Sinai Medical Center, Los Angeles

1081 GN

Brain Research Center B.V, Amsterdam

6525 GA

UMC St Radboud, Nijmegen

8025AZ

Brain Research Center Zwolle, Zwolle

EX4 4RN

University of Exeter, Exeter

E1 2ES

Barts Health NHS Trust, London

W6 8RF

Imperial College Healthcare NHS Trust; Charing Cross Hospital, London

WC1N 3BG

National Hospital for Neurology and Neurosurgery; Leonard Wolfson Experimental Neurology Centre CRF, London

NE4 5PL

Campus for Ageing & Vitality; Clincal Ageing Research Unit, Newcastle

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY